NIH cancer study on Nexrutine
This article was originally published in The Tan Sheet
NIH's National Center for Complementary & Alternative Medicine awards two-year grant to AMC Cancer Research Center to study Next Pharmaceuticals' Nexrutine anti-inflammatory dietary supplement ingredient as a prostate cancer preventive agent, the Denver Colo.-based research institute announces Sept. 16. Nexrutine is a plant extract from bark of Phellodendron trees commonly found in Asia. AMC plans to determine the molecular mechanism underlying the ingredient's efficacy. Previous studies by Dr. Pratap Kumar, the proposal's principal investigator, found Nexrutine inhibits prostate cancer cell growth...
You may also be interested in...
A recent FDA action plan on artificial intelligence and machine learning (AI/ML) medical software could encourage more to jump in, said Eko Chief Medical Officer Adam Saltman.
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.
Efficacy against moderate to severe/critical COVID-19 was 66%-67%, well above the FDA’s stated 50% efficacy threshold for an EUA but far short of the 94%+ efficacy rates posted by the Pfizer and Moderna vaccines against symptomatic disease; agency says efficacy against specific variants cannot be evaluated at this time because sequencing data are incomplete.